Opinion

Video

Exploring Results from CAPItello-291 Trial

William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.

  1. In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?
    1. What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
  2. How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Related Videos
Ticiana Leal, MD, Emory Winship Cancer Institute
Javed Butler, MD
This series features 1 kol.
Anna Mueller, MD, Amir Ahmadi, MD
Deepak Bhatt, MD
John McMurray, MD
Chris Kramer, MD, American College of Cardiology
Dipti Itchhaporia, MD
Martha Gulati, MD
This series features 1 kol.
Related Content
COPD drawing | Image Credit: Ivelin Radkov - stock.adobe.com
September 6th 2024

Roflumilast Linked to Higher 5-Year Mortality in Patients With COPD in US, Germany

Brooke McCormick
A small 5-year all-cause mortality risk increase among patients with chronic obstructive pulmonary disease (COPD) using roflumilast was found in Germany and the US.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Serious GP doctor showing tablet screen to old 70s female patient, explaining electronic prescription, medical screening, examination result, giving consultation - ARMMY PICCA - stock.adobe.com
September 6th 2024

Research Suggests Psychedelics Are Well Tolerated, but Calls for Improved Monitoring

Giuliana Grossi
While psychedelics like LSD and psilocybin are generally well tolerated in clinical and research settings, study authors suspect inconsistent reporting of adverse events.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
heartbeats-Robert-stock.adobe.com
September 6th 2024

ESC Congress 2024 Recap: New Guidelines, Breakthrough Trials, and Personalized Cardiology

Giuliana Grossi
Lead investigators, presenters, and the chair of this year’s European Society of Cardiology Congress, John McMurray, MD, discussed the meeting highlights and recapped important data.
heart check with magnifying glass | Image Credit: Atlantist studio-stock.adobe.com
September 6th 2024

ESC 2024: Advancing Care With New Cardiovascular Research

Maggie L. Shaw
At the 2024 European Society of Cardiology Congress (ESC), key research in cardiology care included studies conducted on cardiovascular disease risk among women, cardiac distress and smoking, and lipoprotein(a).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo